ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Mar 24, 2023 13:22 JST
Source:
Eisai
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
TOKYO, Mar 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28.
Notable research to be featured in the Scientific Plenary IX: The Best of the Rest session includes a presentation of real-world outcomes and healthcare resource utilization in patients with recurrent or advanced endometrial carcinoma who were rechallenged with platinum chemotherapy in Europe (Abstract: #17). Also to be presented are data from the LEAP (LEnvatinib And Pembrolizumab) clinical program analyzing tumor-response from the lenvatinib (LENVIMA) plus pembrolizumab (KEYTRUDA) arm of the pivotal Phase 3 Study 309/KEYNOTE-775 trial in patients with advanced endometrial carcinoma following at-least one prior platinum-based regimen in any setting (NCT03517449; Abstract: #518).
"We look forward to sharing our data at this year's SGO Annual Meeting, particularly a new study that will be presented in an oral scientific plenary session featuring real-world outcomes in patients with recurrent or advanced endometrial cancer who were rechallenged with platinum chemotherapy," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "We believe this research is important to the healthcare providers and patients we aim to serve because it is essential to understand treatment dynamics and related outcomes in clinical practice. As a human health care company, we remain steadfast in our commitment to advance the science of cancer medicine through the generation of real-world evidence."
In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with Merck's anti-PD-1 therapy pembrolizumab. To date, more than 10 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
For more information, visit www.eisai.com/news/2023/news202322.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi Collaborates with NVIDIA to Accelerate Digital Transformation with Generative AI
Mar 19, 2024 19:11 JST
Mitsubishi Corporation and 7 large international companies join forces to sponsor the creation of a global e-NG coalition
Mar 19, 2024 16:40 JST
Mazda: Permanent Pride of Hiroshima Exhibition Opens April 27
Mar 19, 2024 16:02 JST
TMF Collaborates with the Okinawa Prefectural Police Headquarters to Develop Accident Prevention Approaches Integrating Police Accident Data with Vehicle Data
Mar 19, 2024 12:49 JST
Hitachi Vantara Announces Collaboration with NVIDIA to Create New Portfolio of Industrial AI Solutions
Mar 19, 2024 12:35 JST
Fujitsu Limited announces recruitment plans
Mar 19, 2024 10:34 JST
Nissan and Mitsubishi Corporation agree to explore new business in next-generation-mobility and energy-related services utilizing EVs
Mar 18, 2024 17:29 JST
Fujitsu and AWS will launch a new Modernization Acceleration Joint Initiative to enable customers across industries to drive digital transformation with fast and secure legacy modernization
Mar 18, 2024 16:12 JST
Nissan and Honda to start feasibility study of strategic partnership
Mar 18, 2024 12:14 JST
Mitsubishi Power Achieves #1 Global Gas Turbine Market Share in 2023
Mar 15, 2024 18:34 JST
Mitsubishi Corp to invest in TIER IV: Transforming regional mobility with autonomous driving
Mar 15, 2024 12:36 JST
Hitachi High-Tech Launches High-sensitivity and High-throughput Wafer Surface Inspection System LS9300AD for Wafer Manufacturers
Mar 15, 2024 11:21 JST
Japanese joint research group win Prime Minister's Award with ultra high-performance computing platform using jointly developed 64-qubit quantum computer
Mar 15, 2024 10:19 JST
MHI Establishes GX Solutions Business Domain to Promote Energy Transition Business Growth Strategy
Mar 14, 2024 13:30 JST
Fujitsu and Tokai National Higher Education and Research System collaborate on AI-based space weather research
Mar 14, 2024 10:21 JST
Mitsubishi Corporation, Mitsubishi Fuso Truck and Bus, and Mitsubishi Motors will jointly establish a new company to run an online platform providing comprehensive EV related services
Mar 13, 2024 18:06 JST
MHI Selected as Licensor of CO2 Capture Technology for Leading Low Carbon Hydrogen Production Project in Cheshire, UK
Mar 13, 2024 11:30 JST
GMO Research Activity Support & Technology launches brain MRI analysis tool developed on world class supercomputer Fugaku with Fujitsu Computing as a Service (CaaS)
Mar 12, 2024 10:20 JST
TANAKA Establishes Bonding Technology for High-Density Semiconductor Mounting Using AuRoFUSE(TM) Preforms
Mar 12, 2024 03:00 JST
Hitachi Forges a Three Year Strategic Alliance with AWS to Advance Hybrid Cloud Solutions
Mar 11, 2024 16:44 JST
More Latest Release >>
Related Release
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
3/6/2024 5:47:00 PM JST
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
2/21/2024 3:26:00 PM JST
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2024 9:35:00 AM JST
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
2/16/2024 9:31:00 AM JST
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
2/1/2024 6:04:00 PM JST
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
1/26/2024 4:26:00 PM JST
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
1/18/2024 3:12:00 PM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
1/17/2024 5:08:00 PM JST
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
1/16/2024 10:25:00 AM JST
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
1/11/2024 4:33:00 PM JST
More Press release >>